News
All News
Contributors
Money Matters
Media
All Videos
Expert Interviews
Medical World News
Podcasts
Beyond The Walls
Case Based Roundtable Series
Case of the Quarter
EyeView
Grand Rounds
Insights
Rapid Readout
Special Report
Viewpoints
What’s Your WhEYE?
Conferences
Conference Coverage
Conference Listing
Events
More
Publications
Digital Edition
Europe Ophthalmology Times
Modern Retina
Supplements and Featured Publications
CME
Partners
Resources
Job Board
Sponsored
Subscribe
My Account
News
Media
Conferences
Events
Publications
CME
Partners
Subscribe
Resources
AMD
Biosimilars
COVID-19
Cataract
Cataract Surgery
Cataract Therapeutics
Clinical Diagnosis
On the Orbital Edge
The Residency Report
iOpeners
NeuroOp Guru
Cornea
DME
Dry Eye
Dry Eye Awareness
Gene Therapy
Geographic Atrophy
IOL
IOL Advances
Imaging
Interventional Glaucoma
Glaucoma Awareness
Glaucoma Insights
Therapeutic Glaucoma
OCT
Ocular Allergy
Ocular Surface Disease
Optic Relief
Optometry
Pediatrics
Pharmacy
Practice Management
Indispensable
Presbyopia
Ptosis
Refractive
Refractive Surgery
Retina
Surgery
Technology
Therapeutics
Understanding Antibiotic Resistance
Workplace
Choose Specialty
Spotlight -
Retina
Advertisement
Jeffrey J. Denning
Advertisement
UnCommon Sense, Long Beach CA
Articles by Jeffrey J. Denning
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
Sandoz Canada launches aflibercept biosimilar, Enzeevum
